A new phenolic acid isolated from Salvia miltiorrhiza ameliorates OVA-induced allergic asthma by regulation of Th17/Treg cells and inflammation through the TLR4 pathway

Abstract

Salvia miltiorrhiza (S. miltiorrhiza) represents a crucial component of traditional Chinese medicine, demonstrating effects on blood circulation activation and stasis removal, and has been widely utilized in asthma treatment. This study isolated a novel phenolic acid (S1) from S. miltiorrhiza and investigated its anti-asthmatic activity and underlying mechanisms for the first time. An allergic asthma (AA) model was established using ovalbumin (OVA). The mechanism of S1’s effects on AA was investigated using multi-factor joint analysis, flow cytometry, and co-culture systems to facilitate clinical asthma treatment. S1 (10 or 20 mg·kg⁻¹) was administered daily to mice with OVA-induced AA (OVA-AA) during days 21−25. The study examined airway responsiveness, lung damage, inflammation, and levels of immunoglobulin E (IgE), PGD2, interleukins (IL-4, 5, 10, 13, 17A), tumor necrosis factor α (TNF-α), GM-CSF, CXCL1, CCL11, and mMCP-1. Additionally, mast cell (MC) activation and degranulation were explored, along with T helper type 17 (Th17)/Treg immune cells and TLR4 pathway biomarkers. The antagonistic activity of that specific antagonist of TLR4 (TAK-242) (1 μmol·L⁻¹), a specific TLR4 blocker, against S1 (10 μmol·L⁻¹) was examined in co-cultured 16HBE cells and bone marrow-derived cells (BMDCs) or splenic lymphocytes (SLs) induced with LPS (1 μg·mL⁻¹) to elucidate the TLR4 pathway’s mediating role. S1 demonstrated reduced airway responsiveness, lung damage, and inflammation, with downregulation of IgE, PGD2, interleukins, TNF-α, GM-CSF, CXCL1, CCL11, and mMCP-1. It also impeded MC activation and degranulation, upregulated IL-10, and influenced Th17/Treg immune cell transformation following OVA challenge. Furthermore, S1 inhibited the TLR4 pathway in OVA-AA mice, and TLR4 antagonism enhanced S1’s positive effects. Analysis using an OVA-AA mouse model demonstrated that S1 alleviates AA clinical symptoms, restores lung function, and inhibits airway response. S1’s therapeutic effects occur through regulation of Th17/Treg immune cells and inflammation, attributable at least partially to the TLR4 pathway. This study provides molecular justification for S1 in AA treatment.

Keywords

Asthma / Co-culture / Phenolic acid / Salvia miltiorrhiza / TLR4

References

[1] Tchen S, Vu T, Fleischman M, et al. Assessing prescriber adherence with Global Initiative for Asthma (GINA) guideline-recommended reliever therapy. Intern Emerg Med. 2023; 18(7):2029-2036. https://doi.org/10.1007/s11739-023-03401-w.

[2] Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023; 11(7):589. https://doi.org/10.1016/s2213-2600(23)00230-8.

[3] Baker JA, Houin PR. Comparison of national and global asthma management guiding documents. Respir Care. 2023; 68(1):114-128. https://doi.org/10.4187/respcare.10254.

[4] Nissly T. Asthma management: How the guidelines compare. J Fam Pract. 2022; 71(9):392-397. https://doi.org/10.12788/jfp.0501.

[5] Pollack M, Gandhi H, Tkacz J, et al. The use of short-acting bronchodilators and cost burden of asthma across global initiative for asthma-based severity levels: Insights from a large US commercial and managed Medicaid population. J Manag Care Specialty Pharm. 2022; 28(8):881-891. https://doi.org/10.18553/jmcp.2022.21498.

[6] Garg R, Piplani M, Upadhayay A, et al. A review on comparison of allopathic medicines to other drug therapies in the management of asthma. Infect Disord Drug Targets. 2024; 24(2):e201023222496. https://doi.org/10.2174/0118715265249796231018050521.

[7] Komlósi ZI, van de Veen W, Kovács N, et al. Cellular and molecular mechanisms of allergic asthma. Mol Aspects Med. 2022;85:100995. https://doi.org/10.1016/j.mam.2021.100995.

[8] Jasemi SV, Khazaei H, Morovati MR, et al. Phytochemicals as treatment for allergic asthma: Therapeutic effects and mechanisms of action. Phytomedicine. 2024;122:155149. https://doi.org/10.1016/j.phymed.2023.155149.

[9] Huang Y, Qiu C. Research advances in airway remodeling in asthma: A narrative review. Ann Transl Med. 2022; 10(18):1023. https://doi.org/10.21037/atm-22-2835.

[10] Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. Cell Tissue Res. 2017; 367(3):551-569. https://doi.org/10.1007/s00441-016-2566-8.

[11] Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021; 21(11):739-751. https://doi.org/10.1038/s41577-021-00538-7.

[12] Deckers J, Branco Madeira F, Hammad H.Innate immune cells in asthma. Trends Immunol. 2013; 34(11):540-547. https://doi.org/10.1016/j.it.2013.08.004.

[13] Misra RS. A review of the CD4⁺T cell contribution to lung infection, inflammation and repair with a focus on wheeze and asthma in the pediatric population. EC Microbiol. 2014;1:4-14.

[14] Bryant N, Muehling LM.T-cell responses in asthma exacerbations. Ann Allergy Asthma Immunol. 2022; 129(6):709-718. https://doi.org/10.1016/j.anai.2022.07.027.

[15] Boonpiyathad T, Sözener ZC, Satitsuksanoa P, et al.Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333. https://doi.org/10.1016/j.smim.2019.101333.

[16] Zhang Q, Zeng M, Zhang B, et al. Salvianolactone acid A isolated from Salvia miltiorrhiza ameliorates lipopolysaccharide-induced acute lung injury in mice by regulating PPAR-γ. Phytomedicine. 2022;105:154386. https://doi.org/10.1016/j.phymed.2022.154386.

[17] Zeng M, Feng A, Ren Y, et al. Salvia miltiorrhiza Bunge extract and Przewalskin ameliorate Bleomycin-induced pulmonary fibrosis by inhibition of apoptosis, oxidative stress and collagen deposition via the TGF-β1 pathway. Phytomedicine. 2024;125:155339. https://doi.org/10.1016/j.phymed.2024.155339.

[18] Ren YJ, Cao YG, Zeng MN, et al. Salviamilthone A-O, diterpenoid quinones from Salvia miltiorrhiza. Phytochemistry. 2023;215:113840. https://doi.org/10.1016/j.phytochem.2023.113840.

[19] Ren YJ, Cao YG, Zeng MN, et al. Diterpenoid quinones from the Salvia miltiorrhiza and their lung protective activity. Fitoterapia. 2023;167:105474. https://doi.org/10.1016/j.fitote.2023.105474.

[20] Ren YJ, Cao YG, Zeng MN, et al. Two new diterpenoid quinones with lung protective activity from the roots of Salvia miltiorrhiza. Phytochem Lett. 2022; 51:1-4. https://doi.org/10.1016/j.phytol.2022.06.006.

[21] Ren YJ, Cao YG, Zeng MN, et al. Ten undescribed diterpenoid quinones derived from the Salvia miltiorrhiza. Phytochemistry. 2022;200:113224. https://doi.org/10.1016/j.phytochem.2022.113224.

[22] Jia J, Zeng M, Zhu D, et al. An amide alkaloid isolated from ephedra sinica ameliorates OVA-induced allergic asthma by inhibiting mast cell activation and dendritic cell maturation. Int J Mol Sci. 2022; 23(21):13541. https://doi.org/10.3390/ijms232113541.

[23] Li YC, Huang LT, Li JL, et al. Targeting TLR4 and regulating the Keap1/Nrf2 pathway with andrographolide to suppress inflammation and ferroptosis in LPS-induced acute lung injury. Chin J Nat Med. 2024; 22(10):914-928. https://doi.org/10.1016/S1875-5364(24)60727-2.

[24] Dat NT, Jin X, Lee JH, et al.Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J Nat Prod. 2007; 70(7):1093-1097. https://doi.org/10.1021/np060482d.

[25] Padem N, Saltoun C. Classification of asthma. Allergy Asthma Proc. 2019; 40(6):385-388. https://doi.org/10.2500/aap.2019.40.4253.

[26] Sockrider M, Fussner L. What is asthma? Am J Respir Crit Care Med. 2020; 202(9):P25-P26. https://doi.org/10.1164/rccm.2029p25.

[27] Alagappan VKT, de Boer WI, Misra VK, et al. Angiogenesis and vascular remodeling in chronic airway diseases. Cell Biochem Biophys. 2013; 67(2):219-234. https://doi.org/10.1007/s12013-013-9713-6.

[28] Xu Z, Forno E, Sun Y, et al. Nasal epithelial gene expression and total IgE in children and adolescents with asthma. J Allergy Clin Immunol. 2024; 153(1):122-131. https://doi.org/10.1016/j.jaci.2023.09.014.

[29] Hammad H, Lambrecht BN.The basic immunology of asthma. Cell. 2021; 184(6):1469-1485. https://doi.org/10.1016/j.cell.2021.02.016.

[30] Murphy RC, Hallstrand TS. Exploring the origin and regulatory role of mast cells in asthma. Curr Opin Allergy Clin Immunol. 2021; 21(1):71-78. https://doi.org/10.1097/aci.0000000000000703.

[31] León B, Ballesteros-Tato A. Modulating Th 2 cell immunity for the treatment of asthma. Front Immunol. 2021;12:637948. https://doi.org/10.3389/fimmu.2021.637948.

[32] Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene hypothesis. Nat Immunol. 2017; 18(10):1076-1083. https://doi.org/10.1038/ni.3829.

[33] Nie Y, Yang B, Hu J, et al. Bruceine D ameliorates the balance of Th1/Th2 in a mouse model of ovalbumin-induced allergic asthma via inhibiting the NOTCH pathway. Allergol Immunopathol (Madr). 2021; 49(6):73-79. https://doi.org/10.15586/aei.v49i6.499.

[34] Georas SN, Rezaee F. Epithelial barrier function: At the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014; 134(3):509-520. https://doi.org/10.1016/j.jaci.2014.05.049.

[35] Holtzman MJ, Byers DE, Alexander-Brett J, et al. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol. 2014; 14(10):686-698. https://doi.org/10.1038/nri3739.

[36] Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. J Clin Investig. 2019; 129(4):1441-1451. https://doi.org/10.1172/jci124606.

[37] Elieh Ali Komi D, Bjermer L. Mast cell-mediated orchestration of the immune responses in human allergic asthma: current insights. Clin Rev Allergy Immunol. 2019; 56(2):234-247. https://doi.org/10.1007/s12016-018-8720-1.